This implies that passive immunization with tau antibodies is often a feasible therapeutic focus on and that the CSF volume of p-tau262/356 or in the microtubule binding area (MTBD) can serve as a helpful biomarker of tau pathology to monitor tau therapeutics in clinical trials.Bienvenue to Singulart. Learn Daring, inspiring creations to elevate yo